JP2014503188A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503188A5 JP2014503188A5 JP2013535577A JP2013535577A JP2014503188A5 JP 2014503188 A5 JP2014503188 A5 JP 2014503188A5 JP 2013535577 A JP2013535577 A JP 2013535577A JP 2013535577 A JP2013535577 A JP 2013535577A JP 2014503188 A5 JP2014503188 A5 JP 2014503188A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- separate anti
- composition
- molecules
- heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 23
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000178 monomer Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40878210P | 2010-11-01 | 2010-11-01 | |
| DKPA201000988 | 2010-11-01 | ||
| US61/408,782 | 2010-11-01 | ||
| DKPA201000988 | 2010-11-01 | ||
| DKPA201100672 | 2011-09-05 | ||
| DKPA201100672 | 2011-09-05 | ||
| US201161531407P | 2011-09-06 | 2011-09-06 | |
| US61/531,407 | 2011-09-06 | ||
| PCT/IB2011/054834 WO2012059857A2 (en) | 2010-11-01 | 2011-10-31 | Pan-her antibody composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503188A JP2014503188A (ja) | 2014-02-13 |
| JP2014503188A5 true JP2014503188A5 (enExample) | 2014-12-18 |
| JP6033783B2 JP6033783B2 (ja) | 2016-11-30 |
Family
ID=59014867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535578A Expired - Fee Related JP6186277B2 (ja) | 2010-11-01 | 2011-10-31 | 抗ｈｅｒ３抗体および組成物 |
| JP2013535577A Expired - Fee Related JP6033783B2 (ja) | 2010-11-01 | 2011-10-31 | Ｐａｎ−ｈｅｒ抗体組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535578A Expired - Fee Related JP6186277B2 (ja) | 2010-11-01 | 2011-10-31 | 抗ｈｅｒ３抗体および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9217039B2 (enExample) |
| EP (3) | EP2635605B1 (enExample) |
| JP (2) | JP6186277B2 (enExample) |
| KR (2) | KR101862832B1 (enExample) |
| AU (2) | AU2011324871B2 (enExample) |
| CA (2) | CA2816519C (enExample) |
| DK (1) | DK2635604T3 (enExample) |
| ES (2) | ES2692379T3 (enExample) |
| IL (2) | IL225954B (enExample) |
| MX (2) | MX347981B (enExample) |
| PL (1) | PL2635604T3 (enExample) |
| TW (1) | TW201231066A (enExample) |
| WO (2) | WO2012059857A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2331577B1 (en) * | 2008-08-29 | 2017-06-07 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| EP2337800B1 (en) | 2008-09-15 | 2013-10-02 | Yeda Research and Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
| PH12012501157A1 (en) | 2009-12-22 | 2012-10-29 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| KR101862832B1 (ko) | 2010-11-01 | 2018-05-30 | 심포젠 에이/에스 | Ｐａｎ―ｈｅｒ 항체 조성물 |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| JP2014509593A (ja) * | 2011-03-15 | 2014-04-21 | メリマック ファーマシューティカルズ インコーポレーティッド | ＥｒｂＢ経路阻害剤に対する耐性の克服 |
| EP2710038B1 (en) * | 2011-05-16 | 2018-01-17 | Yeda Research and Development Co. Ltd. | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
| KR101662412B1 (ko) * | 2011-07-01 | 2016-10-04 | 암젠 인크 | 포유동물 세포 배양 |
| MX350957B (es) | 2011-11-23 | 2017-09-27 | Medimmune Llc | Moleculas de union especificas para her3 y usos de las mismas. |
| RU2014136886A (ru) * | 2012-03-27 | 2016-05-20 | Дженентек, Инк. | Диагностика и виды лечения, связанные с ингибиторами her3 |
| HK1202431A1 (en) | 2012-05-02 | 2015-10-02 | Symphogen A/S | Humanized pan-her antibody compositions |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| AU2014323523B2 (en) | 2013-09-20 | 2020-02-20 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2016038610A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| ES2748295T3 (es) | 2014-09-16 | 2020-03-16 | Symphogen As | Anticuerpos anti-MET y composiciones |
| EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| CN108602890A (zh) | 2015-12-11 | 2018-09-28 | 瑞泽恩制药公司 | 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法 |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
| KR102737715B1 (ko) | 2017-04-05 | 2024-12-03 | 르 라보레또레 쎄르비에르 | Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법 |
| KR102721137B1 (ko) | 2017-05-30 | 2024-10-25 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물 |
| CA3060984A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| US11359024B2 (en) * | 2018-09-07 | 2022-06-14 | Pfizer Inc. | Anti-AVB8 antibodies and compositions and uses thereof |
| CN114426578B (zh) * | 2019-02-14 | 2025-03-21 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
| IL285490B2 (en) * | 2019-02-14 | 2026-03-01 | Merus Nv | Combinations of binding sites that bind EGFR, HER2, and HER3 |
| JP7774293B2 (ja) * | 2019-07-24 | 2025-11-21 | 国立研究開発法人科学技術振興機構 | 抗体酵素の革新的製造技術 |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20240101666A1 (en) | 2020-10-23 | 2024-03-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| AU2021414400A1 (en) | 2020-12-31 | 2023-08-17 | Innate Pharma | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| CN119365495A (zh) | 2022-05-27 | 2025-01-24 | 赛诺菲 | 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物 |
| IL324556A (en) | 2023-05-19 | 2026-01-01 | Servier Lab | Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| AU727082B2 (en) | 1996-03-27 | 2000-11-30 | Genentech Inc. | ErbB3 antibodies |
| AUPQ105799A0 (en) * | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| AU2001247616B2 (en) * | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| WO2004087763A1 (ja) * | 2003-03-31 | 2004-10-14 | Chugai Seiyaku Kabushiki Kaisha | Ｃｄ２２に対する改変抗体およびその利用 |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| PL1787126T3 (pl) | 2004-07-20 | 2010-03-31 | Symphogen As | Sposób charakteryzowania poliklonalnej linii komórkowej |
| HRP20141111T1 (hr) | 2004-07-22 | 2015-01-02 | Genentech, Inc. | Sastav her2-protutijela |
| ZA200704796B (en) | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| SG178789A1 (en) * | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| NZ597466A (en) | 2007-03-01 | 2013-08-30 | Symphogen As | Recombinant anti-epidermal growth factor receptor antibody compositions |
| HRP20100640T1 (hr) | 2007-05-25 | 2010-12-31 | Symphogen A/S | Postupak proizvodnje rekombinantnog poliklonskog proteina |
| RU2476886C2 (ru) | 2007-11-22 | 2013-02-27 | Симфоген А/С | Способ характеризации рекомбинантного поликлонального белка |
| CA2722348A1 (en) | 2008-04-23 | 2009-10-29 | Symphogen A/S | Methods for manufacturing a polyclonal protein |
| WO2010019952A2 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
| EP2331577B1 (en) * | 2008-08-29 | 2017-06-07 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| AU2009301505A1 (en) * | 2008-10-06 | 2010-04-15 | Symphogen A/S | Method for identifying and selecting drug candidates for combinatorial drug products |
| SG10201402742YA (en) * | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| JP5587975B2 (ja) * | 2009-04-07 | 2014-09-10 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体 |
| PT2417156E (pt) * | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| WO2010127181A1 (en) | 2009-04-29 | 2010-11-04 | Trellis Bioscience, Inc. | Improved antibodies immunoreactive with heregulin-coupled her3 |
| SG177560A1 (en) * | 2009-07-06 | 2012-03-29 | Hoffmann La Roche | Bi-specific digoxigenin binding antibodies |
| KR20120059568A (ko) * | 2009-08-21 | 2012-06-08 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ３의 엑토도메인에 대한 항체 및 이의 용도 |
| JP2013507378A (ja) | 2009-10-09 | 2013-03-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途 |
| BR112012012160B1 (pt) | 2009-11-13 | 2022-04-26 | Amgen, Inc. | Material e métodos para tratar ou prevenir doenças associadas ao her-3 |
| JP6039428B2 (ja) | 2010-03-04 | 2016-12-07 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | 抗ｈｅｒ２抗体および組成物 |
| US8481687B2 (en) | 2010-04-09 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
| SG187908A1 (en) | 2010-08-20 | 2013-03-28 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| KR101862832B1 (ko) | 2010-11-01 | 2018-05-30 | 심포젠 에이/에스 | Ｐａｎ―ｈｅｒ 항체 조성물 |
-
2011
- 2011-10-31 KR KR1020137013561A patent/KR101862832B1/ko not_active Expired - Fee Related
- 2011-10-31 AU AU2011324871A patent/AU2011324871B2/en not_active Ceased
- 2011-10-31 EP EP11837656.5A patent/EP2635605B1/en not_active Not-in-force
- 2011-10-31 ES ES11837656.5T patent/ES2692379T3/es active Active
- 2011-10-31 EP EP11797354.5A patent/EP2635604B1/en not_active Not-in-force
- 2011-10-31 JP JP2013535578A patent/JP6186277B2/ja not_active Expired - Fee Related
- 2011-10-31 JP JP2013535577A patent/JP6033783B2/ja not_active Expired - Fee Related
- 2011-10-31 MX MX2013004899A patent/MX347981B/es active IP Right Grant
- 2011-10-31 WO PCT/IB2011/054834 patent/WO2012059857A2/en not_active Ceased
- 2011-10-31 KR KR1020137013552A patent/KR101773120B1/ko not_active Expired - Fee Related
- 2011-10-31 ES ES11797354.5T patent/ES2616961T3/es active Active
- 2011-10-31 MX MX2013004897A patent/MX348637B/es active IP Right Grant
- 2011-10-31 EP EP16200853.6A patent/EP3156421B1/en not_active Not-in-force
- 2011-10-31 WO PCT/IB2011/054835 patent/WO2012059858A1/en not_active Ceased
- 2011-10-31 PL PL11797354T patent/PL2635604T3/pl unknown
- 2011-10-31 AU AU2011324870A patent/AU2011324870B2/en not_active Ceased
- 2011-10-31 DK DK11797354.5T patent/DK2635604T3/en active
- 2011-10-31 CA CA2816519A patent/CA2816519C/en not_active Expired - Fee Related
- 2011-10-31 CA CA2816520A patent/CA2816520C/en not_active Expired - Fee Related
- 2011-10-31 US US13/882,807 patent/US9217039B2/en not_active Expired - Fee Related
- 2011-11-01 TW TW100139897A patent/TW201231066A/zh unknown
-
2013
- 2013-04-25 IL IL225954A patent/IL225954B/en active IP Right Grant
- 2013-04-25 IL IL225953A patent/IL225953A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503189A5 (enExample) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2018503380A5 (enExample) | ||
| JP2020023523A5 (enExample) | ||
| NZ604007A (en) | Monoclonal antibodies against her2 epitope | |
| MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
| JP2014502955A5 (enExample) | ||
| JP2015517300A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| HRP20201375T1 (hr) | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE | |
| IL299221A (en) | Cd3 binding antibodies | |
| JP2011046732A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| JP2015535828A5 (enExample) | ||
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| JP2019510733A5 (enExample) | ||
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| JP2017535257A5 (enExample) | ||
| WO2016081746A8 (en) | Antibodies comprising modified heavy constant regions | |
| RU2011116112A (ru) | Биспецифические анти-egfr/анти-igf-1r антитела | |
| EP4309740A3 (en) | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof | |
| EP3539988A3 (en) | Monoclonal antibodies against her2 | |
| WO2012143524A3 (en) | Bispecific antibodies against her2 and cd3 |